AI tailors cancer treatment for best possible outcome


AI tailors cancer treatment for best possible outcome

  • March 25, 2019

Professor Dean Ho, Director of the Singapore Institute for Neurotechnology (Sinapse) and BIGHEART principal investigator, and Assistant Professor Edward Chow (Cancer Science Institute of Singapore) have been featured in a Straits Times article about their artificial intelligence (AI) systems which optimise drug selection and dosage for individuals to improve the treatment of diseases. 

Over 30 patients have been treated successfully using their complementary AI platforms QPOP (Quadratic Phenotypic Optimisation Platform) and CURATE.AI for cancers, infectious diseases, as well as cognitive training to improve brain function. The team is currently recruiting 195 participants for three different clinical trials ranging from multiple myeloma, liver transplant immunosuppression and cognitive training. 

Please click the links below for the news article: